On March 5, 2019, the FDA approved esketamine (Spravato) nasal spray as add-on therapy to traditional antidepressant medications for treatment-resistant depression (TRD). In this article, I will describe the events that led to esketamine’s development, review the data submitted to the FDA, and discuss what the future might hold for esketamine.

Certain psychiatric treatments require both the healthcare provider and patient to enroll in a Risk Evaluation and Mitigation Strategy (REMS) program before they are administered. Here are links to enroll.

Does ginger ale treat nausea? Not really, but Dr. Mago has some better ideas, and this interview is packed with new and practical ways to manage common side effects of psychiatric medications.

Solriamfetol (Sunosi) was just approved for excessive daytime sleepiness in narcolepsy and sleep apnea, but it may have important psychiatric effects as well.

Every week of depression takes a toll on infant development, so this rapid-acting treatment fills a unique need. Here we review the clinical data and the pragmatics of getting patients connected with the therapy.

The way we taper serotonergic antidepressants may need to be rethought, and this study suggests a new method.

Use this PDF tool to check if the patient is having any SSRI withdrawal symptoms at baseline.

Why does stroke matter in bipolar disorder? Because it’s the leading cause of death for these patients. Some mood stabilizers raise the stroke risk, while others do not.

Two medications show promise in OCD, and their mechanisms are novel: one glutamatergic, one dopaminergic.